156 related articles for article (PubMed ID: 8201387)
21. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
Klaassen U; Wilke H; Seeber S
J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
[TBL] [Abstract][Full Text] [Related]
22. Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naive metastatic breast cancer patients.
Berruti A; Bitossi R; Bottini A; Bonardi S; Donadio M; Nigro C; Bertetto O; Danese S; Bertone E; Sarobba MG; Farris A; Katsaros D; Castiglione F; Volpe T; Lattuada S; Mancarella S; Dogliotti L
Eur J Cancer; 2005 Jan; 41(2):249-55. PubMed ID: 15661550
[TBL] [Abstract][Full Text] [Related]
23. Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report.
Zaniboni A; Barni S; Labianca R; Marini G; Pancera G; Giaccon G; Piazza E; Signaroldi A; Legnani W; Luporini G
Cancer; 1995 Nov; 76(10):1694-9. PubMed ID: 8625036
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
Thuss-Patience PC; Kretzschmar A; Repp M; Kingreen D; Hennesser D; Micheel S; Pink D; Scholz C; Dörken B; Reichardt P
J Clin Oncol; 2005 Jan; 23(3):494-501. PubMed ID: 15659494
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer.
Evans TR; Lofts FJ; Mansi JL; Glees JP; Dalgleish AG; Knight MJ
Br J Cancer; 1996 May; 73(10):1260-4. PubMed ID: 8630289
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer.
Zhang CX; Huang S; Xu N; Fang JW; Shen P; Bao YH; Mou BH; Shi MG; Zhong XL; Xiong PJ
Anticancer Drugs; 2007 Jun; 18(5):581-6. PubMed ID: 17414627
[TBL] [Abstract][Full Text] [Related]
27. [Phase II study of docetaxel plus epirubicin versus docetaxel plus cisplatin as first-line chemotherapy for advanced breast cancer].
Wang YJ; Wu Q; Su FX; Zhou LZ; Ye ZB; Yang JQ; Ren H; Zhang J; Ding G; Fu Q; Wang N
Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):541-4. PubMed ID: 19062725
[TBL] [Abstract][Full Text] [Related]
28. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours.
Ellis PA; Norman A; Hill A; O'Brien ME; Nicolson M; Hickish T; Cunningham D
Eur J Cancer; 1995 Sep; 31A(10):1594-8. PubMed ID: 7488407
[TBL] [Abstract][Full Text] [Related]
29. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
[TBL] [Abstract][Full Text] [Related]
30. Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas.
Sun W; Metz JM; Gallagher M; O'Dwyer PJ; Giantonio B; Whittington R; Haller DG
Cancer Chemother Pharmacol; 2011 Mar; 67(3):621-7. PubMed ID: 20495918
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
32. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
Ocvirk J; Reberšek M; Skof E; Hlebanja Z; Boc M
Am J Clin Oncol; 2012 Jun; 35(3):237-41. PubMed ID: 21399488
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of cisplatin, epirubicin and continuous infusion of 5-fluorouracil in patients with advanced intrahepatic cholangiocellular carcinoma (ICC).
Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
Hepatogastroenterology; 2008; 55(85):1380-4. PubMed ID: 18795694
[TBL] [Abstract][Full Text] [Related]
34. Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer.
Cancello G; Bagnardi V; Sangalli C; Montagna E; Dellapasqua S; Sporchia A; Iorfida M; Viale G; Barberis M; Veronesi P; Luini A; Intra M; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2015 Aug; 15(4):259-65. PubMed ID: 25933934
[TBL] [Abstract][Full Text] [Related]
35. Epirubicin, cisplatin, oral UFT, and calcium folinate in advanced gastric carcinoma.
Kim YH; Kim BS; Seo JH; Choi CW; Kim JS; Chun HJ; Hyun JH; Kim JS
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):64-8. PubMed ID: 10442365
[TBL] [Abstract][Full Text] [Related]
36. Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site.
Karapetis CS; Yip D; Virik K; Strickland A; Ryder K; Cowling M; Harper PG
Med Oncol; 2001; 18(1):23-32. PubMed ID: 11778966
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
[TBL] [Abstract][Full Text] [Related]
38. Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study.
Nielsen D; Dombernowsky P; Larsen SK; Hansen OP; Skovsgaard T
Cancer Chemother Pharmacol; 2000; 46(6):459-66. PubMed ID: 11138459
[TBL] [Abstract][Full Text] [Related]
39. A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer.
Rocca A; Peruzzotti G; Ghisini R; Viale G; Veronesi P; Luini A; Intra M; Pietri E; Curigliano G; Giovanardi F; Maisonneuve P; Goldhirsch A; Colleoni M
Anticancer Drugs; 2006 Nov; 17(10):1201-9. PubMed ID: 17075320
[TBL] [Abstract][Full Text] [Related]
40. Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM).
Gebbia V; Caruso M; Borsellino N; Ajello R; Tirrito ML; Chiarenza M; Valenza R; Verderame F; Varvara F; Marrazzo A; Bajardi E; Ferrao F; Bordonaro R; Tralongo P
Anticancer Res; 2006; 26(4B):3143-50. PubMed ID: 16886648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
